- cafead Feb 06, 2023 at 10:42: AM
via Two years ago private device makers’ ardour for going public via a merger with a special purpose acquisition company was at fever pitch. As market sentiment sank into despondency over the course of last year, enthusiasm slackened and medtech Spac deals slowed from a flood to a trickle.
The performance of the 26 medtechs that went public via Spac deals over the last two years has been woeful. Only one has seen its enterprise value exceed the figure promised when the Spac merger was announced, and four now trade at a negative enterprise value, indicating that these groups are trading below cash.
article source
The performance of the 26 medtechs that went public via Spac deals over the last two years has been woeful. Only one has seen its enterprise value exceed the figure promised when the Spac merger was announced, and four now trade at a negative enterprise value, indicating that these groups are trading below cash.
article source